Snehal Gis: Gene Therapy Revolutionizing the Hemophilia Treatment Landscape
Snehal Gis, Senior Digital Analyst Manager and Senior Research Associate at Global Insight Services shared a post on LinkedIn:
”The Hemophilia Gene Therapy Market is entering a transformative phase, driven by the promise of long-term or potentially curative treatments for patients suffering from hemophilia, a rare genetic bleeding disorder.
Unlike traditional therapies that rely on frequent factor replacement infusions, gene therapy introduces functional copies of defective genes into a patient’s cells, enabling the body to produce clotting factors naturally.
This shift represents a paradigm change in treatment approaches, offering improved quality of life and reduced lifetime healthcare costs.
Click to Request a Sample of this Report for Additional Market Insights.”
Stay updated with Hemostasis Today.
-
May 14, 2026, 14:43Sharon Bukola Afolabi: Why Standing Up Is a Bigger Workout for Your Heart Than You Think
-
May 14, 2026, 14:37Grigoris Gerotziafas: Join Our Workshop on Advancing Guideline Adoption in Cancer-Associated Thrombosis at ISTH 2026
-
May 14, 2026, 14:31Jonathan Douxfils: A Critical Review of NETosis Measurement Methods and the Need for Standardization
-
May 14, 2026, 14:21Mavis Agnes Kisakye: With Pride and Gratitude Haemophilia Foundation of Uganda Accepts the Project of the Year 2026 Award
-
May 14, 2026, 14:14Aikati Anastasiou: Blood Pressure Variability in Rescue Stenting for Acute Ischaemic Stroke
-
May 14, 2026, 14:00Amro Al-Manasrah: Coronary Reperfusion Injury Beyond Large-Vessel Occlusion
-
May 14, 2026, 13:54Abdul Mannan: The Dual Biology of the Sickle Cell Mutation
-
May 14, 2026, 13:54Pauline Nerwande: Hemostasis and the Balance Between Bleeding and Thrombosis
-
May 14, 2026, 13:53Anna Oleksiak: Managing Anticoagulation Decisions in Critically Ill Cardiac Patients